Molecular sputum analysis for the diagnosis of lung cancer

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 530-537

  Hubers, A J ^a   Prinsen, C F M ^b   Sozzi, G ^c   Witte, B I ^a   Thunnissen, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; BIOLOGICAL MARKER; COMPLEMENT FACTOR H; MESSENGER RNA; MICRORNA; MICRORNA 155; MICRORNA 200B; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 375; MICRORNA 486; MICRORNA 708; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CYTOLOGY; DNA METHYLATION; EML4 ALK GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HETEROZYGOSITY LOSS; HUMAN; INFRARED SPECTROSCOPY; LUNG CANCER; MUTATIONAL ANALYSIS; NORE1A GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE K RAS; P16 GENE; P53 GENE; PRIORITY JOURNAL; PROMOTER REGION; RASSF1A GENE; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TUMOR SUPPRESSOR GENE; CHEMISTRY; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SPUTUM;

BIOMARKERS, TUMOR; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; PROMOTER REGIONS, GENETIC; SPUTUM;

EID: 84883140244     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.393     Document Type: Review

References (77)

1. Ammanagi AS, Dombale VD, Miskin AT, Dandagi GL, Sangolli S.S. (2012) Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man's bronchoscopy!). Lung India 29: 19-23.
2. Arvanitis DA, Papadakis E, Zafiropoulos A, Spandidos DA (2003) Fractional allele loss is a valuable marker for human lung cancer detection in sputum. Lung Cancer 40: 55-66.
3. Baryshnikova E, Destro A, Infante MV, Cavuto S, Cariboni U, Alloisio M, Ceresoli GL, Lutman R, Brambilla G, Chiesa G, Ravasi G, Roncalli M (2008) Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res 14: 1913-1919.
4. Belinsky SA, Grimes MJ, Casas E, Stidley CA, Franklin WA, Bocklage TJ, Johnson DH, Schiller JH (2007) Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 96: 1278-1283.
5. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA, Picchi MA (2005) Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11: 6505-6511.
6. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66: 3338-3344.
7. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896.
8. Boldrini L, Gisfredi S, Ursino S, Camacci T, Baldini E, Melfi F, Fontanini G (2007) Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2: 1086-1090.
9. Castagnaro A, Marangio E, Verduri A, Chetta A, D'Ippolito R, Del Donno M, Olivieri D, Di Cola G (2007) Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res 33: 289-301.
10. Chen J-T, Chen Y-C, Wang Y-C, Tseng R-C, Chen C-Y, Wang Y-C (2002) Alterations of the p16(ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. Int J Cancer 98: 724-731.
11. Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM, Pastorino U, Sozzi G (2006) Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 118: 1248-1253.
12. Destro A, Bianchi P, Alloisio M, Laghi L, Di Gioia S, Malesci A, Cariboni U, Gribaudi G, Bulfamante G, Marchetti A, Bosari S, Infante M, Ravasi G, Roncalli M (2004) K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 44: 23-32.
13. Durkalski VL, Palesch YY, Lipsitz SR, Rust PF (2003) Analysis of clustered matched-pair data. Stat Med 22: 2417-2428.
14. Eckert KA, Kunkel TA (1991) DNA polymerase fidelity and the polymerase chain reaction. PCR Methods Appl 1: 17-24.
15. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
16. Field JK, Liloglou T, Niaz A, Bryan J, Gosney JR, Giles T, Brambilla C, Brambilla E, Vesin A, Timsit J-F, Hainaut P, Martinet Y, Vignaud JM, Thunnissen FB, Prinsen C, Snijders PJ, Smit EF, Sozzi G, Roz L, Risch A, Becker HD, Elborn JS, Magee ND, Montuenga LM, Pajares MJ, Lozano MD, O'Byrne KJ, Harrison DJ, Niklinski J, Cassidy A (2009) EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. Eur Respir J 34: 1477-1486.
17. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
18. Guzmán L, Depix MS, Salinas AM, Roldán R, Aguayo F, Silva A, Vinet R (2012) Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol 7: 87.
19. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
20. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Wen B,Wu H, Liu Y, Diep D, Briem E, Zhang K, Irizarry RA, Feinberg AP (2011) Increased methylation variation in epigenetic domains across cancer types. Nat Genet 43: 768-775.
21. Hillas G, Moschos C, Dimakou K, Vlastos F, Avgeropoulou S, Christakopoulou I, Rasidakis A, Bakakos P (2008) Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients. Scand J Clin Lab Invest 68: 542-547.
22. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA (2001) Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 7: 5-22.
23. Hsu H-S, Chen T-P, Wen C-K, Hung C-H, Chen C-Y, Chen J-T, Wang Y-C (2007) Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 213: 412-419.
24. Hwang S-H, Kim KU, Kim J-E, Kim H-H, Lee MK, Lee CH, Lee S-Y, Oh T, An S (2011) Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clin Chem Lab Med 49: 699-704.
25. Jakupciak JP, Maragh S, Markowitz ME, Greenberg AK, Hoque MO, Maitra A, Barker PE, Wagner PD, Rom WN, Srivastava S, Sidransky D, O'Connell CD (2008) Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer 8: 285.
26. Jheon S, Hyun D-S, Lee S-C, Yoon G-S, Jeon C-H, Park J-W, Park C-K, Jung M-H, Lee K-D, Chang H-K (2004) Lung cancer detection by a RTnested PCR using MAGE A1-6 common primers. Lung Cancer 43: 29-37.
27. Kalomenidis I, Dimakou K, Kolintza A, Vlami K, Papadakis M, Sotiropoulou C, Orphanidou D, Roussos C, Papiris S (2004) Sputum carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 levels in lung cancer diagnosis. Respirology 9: 54-59.
28. Katz RL, Zaidi TM, Fernandez RL, Zhang J, He W, Acosta C, Daniely M, Madi L, Vargas MA, Dong Q, Gao X, Jiang XGF, Jiang F, Caraway NP, Vaporciyan AA, Roth JA, Spitz MR (2008) Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod Pathol 21: 950-960.
29. Keohavong P, Gao W-M, Zheng K-C, Mady H, Lan Q, Melhem M, Mumford J (2004) Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal Biochem 324: 92-99.
30. Keohavong P, Lan Q, Gao W-M, DeMarini DM, Mass MJ, Li X-M, Roop BC, Weissfeld J, Tian D, Mumford JL (2003) K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China. Lung Cancer 41: 21-27.
31. Keohavong P, Lan Q, Gao W-M, Zheng K-C, Mady HH, Melhem MF, Mumford JL (2005) Detection of p53 and K-ras mutations in sputum of individuals exposed to smoky coal emissions in Xuan Wei County, China. Carcinogenesis 26: 303-308.
32. Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M (2000) Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 18: 3221-3229.
33. Kettunen E, Salmenkivi K, Vuopala K, Toljamo T, Kuosma E, Norppa H, Knuutila S, Kaleva S, Huuskonen MS, Anttila S (2006) Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer 54: 169-176.
34. Konno S, Morishita Y, Fukasawa M, Shu Y, Wang D, Tanaka R, Minami Y, Iijima T, Noguchi M (2004) Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma. Cancer 102: 348-354.
35. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou S-HI, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim W-H, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
36. Leng S, Do K, Yingling CM, Picchi Ma, Wolf HJ, Kennedy TC, Feser WJ, Baron AE, Franklin Wa, Brock MV, Herman JG, Baylin SB, Byers T, Stidley Ca, Belinsky Sa (2012) Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res 18: 3387-3395.
37. Lewis PD, Lewis KE, Ghosal R, Bayliss S, Lloyd AJ, Wills J, Godfrey R, Kloer P, Mur LAJ (2010) Evaluation of FTIR spectroscopy as a diagnostic tool for lung cancer using sputum. BMC Cancer 10: 640.
38. Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, Fang H-B, Katz RL, Stass Sa, Jiang F (2007) Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res 13: 482-487.
39. Liu Y, An Q, Li L, Zhang D, Huang J, Feng X, Cheng S, Gao Y (2003) Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24: 1897-1901.
40. Liu Y, Lan Q, Shen M, Jin J, Mumford J, Ren D, Keohavong P (2008) Aberrant gene promoter methylation in sputum from individuals exposed to smoky coal emissions. Anticancer Res 28: 2061-2066.
41. Martinet N, Alla F, Farré G, Labib T, Drouot H, Vidili R, Picard E, Gaube MP, Le Faou D, Siat J, Borelly J, Vermylen P, Bazarbachi T, Vignaud JM, Martinet Y (2000) Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Res 60: 2869-2875.
42. Mecklenburg I, Stratakis DF, Huber RM, Häussinger K, Morresi-Hauf A, Riethmüller G, Kufer P (2004) Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer. Chest 125: 164S-166S.
43. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N (1984) Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 86: 44-53.
44. National Lung Screening Trial Research TeamAberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks J (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
45. Olaussen KA, Soria J-C, Park YW, Kim HJ, Kim SH, Ro JY, André F, Jang SJ (2005) Assessing abnormal gene promoter methylation in paraffinembedded sputum from patients with NSCLC. Eur J Cancer 41: 2112-2119.
46. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958.
47. Pasrija T, Srinivasan R, Behera D, Majumdar S (2007) Telomerase activity in sputum and telomerase and its components in biopsies of advanced lung cancer. Eur J Cancer 43: 1476-1482.
48. Patz EF, Rossi S, Harpole DH, Herndon JE, Goodman PC (2000) Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 117: 1568-1571.
49. Pio R, Garcia J, Corrales L, Ajona D, Fleischhacker M, Pajares MJ, Cardenal F, Seijo L, Zulueta JJ, Nadal E, Witt C, Lozano MD, Schmidt B, Montuenga LM (2010) Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer. Cancer Epidemiol Biomarkers Prev 19: 2665-2672.
50. Qiu Q, Todd NW, Li R, Peng H, Liu Z, Yfantis HG, Katz RL, Stass Sa, Jiang F (2008) Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer 114: 275-283.
51. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58: 982-990.
52. Risse EK, Van 't Hof MA, Laurini RN, Vooijs PG (1985) Sputum cytology by the Saccomanno method in diagnosing lung malignancy. Diagn Cytopathol 1: 286-291.
53. Rivera MP, Mehta AC (2007) Initial diagnosis of lung cancer: ACCP evidencebased clinical practice guidelines (2nd edition). Chest 132: 131S-148S.
54. Romeo MS, Sokolova IA, Morrison LE, Zeng C, Barón AE, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M (2003) Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn 5: 103-112.
55. Selamat SA, Galler JS, Joshi AD, Fyfe MN, Campan M, Siegmund KD, Kerr KM, Laird-Offringa IA (2011) DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 6: e21443.
56. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
57. Shaw RJ, Akufo-Tetteh EK, Risk JM, Field JK, Liloglou T (2006) Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res 34: e78.
58. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
59. Shin K-C, Lee K-H, Lee C-H, Shin I-H, Suh H-S, Jeon C-H (2012) MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases. Oncol Rep 27: 911-916.
60. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF (2007) Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247: 56-71.
61. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
62. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H (2012) A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 18: 5682-5689.
63. Somers VA, Pietersen AM, Theunissen PH, Thunnissen FB (1998) Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol 16: 3061-3068.
64. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21: 3902-3908.
65. Sun B, Wang H, Wang X, Huang H, Ding W, Jing R, Shi G, Zhu L (2009) A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res 35: 486-500.
66. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta K, Tamura T (2007) Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 13: 5385-5390.
67. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618-6624.
68. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G, Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126: 651-655.
69. Thunnissen FB, Ellis IO, Jütting U (1996) Interlaboratory comparison of DNA image analysis. Anal Cell Pathol 12: 13-24.
70. Thunnissen FBJM (2003) Sputum examination for early detection of lung cancer. J Clin Pathol 56: 805-810.
71. Van der Drift MA, Prinsen CFM, Hol BEA, Bolijn AS, Jeunink MAF, Dekhuijzen PNR, Thunnissen FBJM (2008) Can free DNA be detected in sputum of lung cancer patients? Lung Cancer 61: 385-390.
72. Wang Y-C, Lu Y-P, Tseng R-C, Lin R-K, Chang J-W, Chen J-T, Shih C-M, Chen C-Y (2003) Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111: 887-895.
73. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass Sa, Jiang F (2010) Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67: 170-176.
74. Xing L, Todd NW, Yu L, Fang H, Jiang F (2010) Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 23: 1157-1164.
75. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F (2010) Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127(12): 2870-2878.
76. Zhang L-F, Gao W-M, Gealy R, Weissfeld J, Elder E, Whiteside TL, Keohavong P (2003) Comparison of K-ras gene mutations in tumour and sputum DNA of patients with lung cancer. Biomarkers 8: 156-161.
77. Zöchbauer-Müller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, Minna JD, Gazdar AF (2003) Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 107: 612-616.